Welcome to our dedicated page for Traws Pharma news (Ticker: ONTX), a resource for investors and traders seeking the latest updates and insights on Traws Pharma stock.
Onconova Therapeutics, Inc. (NASDAQ: ONTX) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel small molecule drug candidates aimed at treating cancer. Utilizing a proprietary chemistry platform, Onconova has developed an extensive library of targeted anti-cancer agents designed to interfere with specific cellular pathways critical to cancer cells while minimizing harm to normal cells.
The company's core business is centered on three key product candidates currently in clinical trials and six active pre-clinical programs. These innovative treatments aim to improve patient outcomes by directly addressing the disease, reducing recurrence, and lessening the side effects commonly associated with existing therapies.
Among its recent achievements, Onconova has made significant strides in translational science to better understand the pathways affected by its lead drug candidate, rigosertib. This research is expected to guide future clinical studies and combination treatments for challenging cancer types.
Onconova regularly hosts conference calls and webcasts to update stakeholders on its progress. For instance, the company is scheduled to hold a conference call and webcast on November 14, 2023, to provide further insights into its ongoing projects and recent developments.
Onconova Therapeutics presented new preclinical data on rigosertib at the AACR Targeting RAS Conference, emphasizing its potential to activate an anti-cancer immune response through NLRP3 inflammasome activation. The findings also identify rigosertib's role in inhibiting the RAS-MAPK pathway, critical for cancer progression. The data suggest rigosertib may enhance clinical responses in KRAS-mutated non-small cell lung cancer when combined with checkpoint inhibitors. Notable targets engaged by rigosertib include NQO2, ERO1A, and NEK7, which may inhibit cancer cell proliferation. This research supports ongoing clinical trials and expands understanding of rigosertib's mechanisms.
Onconova Therapeutics announced significant progress in its Phase 2 program evaluating rigosertib for advanced RDEB-associated squamous cell carcinoma (SCC). Both evaluable participants achieved a complete response to treatment, with one patient in remission for over 18 months. The company plans to engage with regulators to discuss an expedited approval pathway for rigosertib, addressing the urgent needs of this rare and deadly condition. Rigosertib is showing promising anti-cancer activity, potentially outperforming existing therapies.
Onconova Therapeutics (NASDAQ: ONTX) is set to participate in the 2023 Guggenheim Oncology Conference in New York City on February 8-9, 2023. CEO Steven Fruchtman will host a fireside chat on February 8 at 10:45 a.m. ET, with a replay available on the company's website. The company will also engage in one-on-one investor meetings at the conference. Onconova is dedicated to advancing innovative anti-cancer therapies, with ongoing Phase 1 studies for its multi-kinase inhibitor narazaciclib and rigosertib evaluations in various cancers. For more details, visit www.onconova.com.
Onconova Therapeutics (NASDAQ: ONTX) announced participation in the Channelchek Takeaway Series, broadcast from the J.P. Morgan Healthcare Conference on January 26, 2023, at 10:00 AM EST. The conference is a premier healthcare investment symposium connecting industry leaders and investors. Steven M. Fruchtman, CEO of Onconova, will provide a corporate overview and answer questions from Noble’s Senior Analyst, Robert LeBoyer. Investors can attend the virtual event free of charge. Onconova is focused on developing innovative cancer treatments, with studies on narazaciclib and rigosertib currently underway.
Onconova Therapeutics (NASDAQ: ONTX) announced the appointments of Peter Atadja, Ph.D., and Trafford Clarke, Ph.D., as independent board members. CEO Steven M. Fruchtman expressed confidence that their extensive experience in pharmaceutical development will aid Onconova in advancing its pipeline. Dr. Atadja noted the potential of the lead asset, narazaciclib, in treating various cancers, while Dr. Clarke emphasized the company’s strong financial foundation and growth prospects in oncology. The firm focuses on developing targeted anti-cancer agents and has ongoing trials for narazaciclib and rigosertib.
Onconova Therapeutics (NASDAQ: ONTX), a clinical-stage biopharmaceutical company, announced participation in the MedInvest Oncology Investor Conference in New York on December 14-15, 2022. CEO Steven M. Fruchtman will present a corporate overview on December 14 at 9:40 a.m. ET. The management team will also hold one-on-one meetings that day. Onconova focuses on developing targeted anti-cancer agents, including narazaciclib and rigosertib, both of which are currently in clinical studies.
Onconova Therapeutics, Inc. (NASDAQ: ONTX) will attend the RHK Capital Disruptive Growth Conference on December 5-6, 2022, in New York City. Mark Guerin, COO and CFO, will present a corporate overview on December 6 at 11:20 a.m. ET.
Onconova focuses on developing innovative cancer treatments, including narazaciclib and rigosertib, which are currently in clinical trials. These drugs are designed to target specific cancer pathways to disrupt cell proliferation, with ongoing studies in the U.S. and China.
Onconova Therapeutics announced the initiation of a Phase 1/2a trial for narazaciclib combined with letrozole to treat recurrent low-grade endometrioid endometrial cancer (LGEEC), expected to start in Q1 2023, with preliminary data in Q4 2023. The Q3 2022 financial report revealed cash reserves of $42.6 million, sufficient to fund operations until 2024. R&D expenses increased to $3.6 million, while general and administrative costs decreased slightly to $2.1 million. The net loss was $5.4 million for the quarter, equating to $0.26 per share, compared to a prior loss of $3.5 million.
Onconova Therapeutics (NASDAQ: ONTX) plans to report its Q3 2022 financial results on November 14, 2022. A conference call and webcast will take place at 4:30 p.m. ET that day to discuss the financial outcomes and updates on its pipeline programs. Onconova is focusing on developing novel cancer treatments, including its multi-kinase inhibitor narazaciclib and rigosertib, currently in various clinical studies. Interested participants can join the call by phone or online via the company's website.
Onconova Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the Ladenburg Thalmann 2022 Healthcare Conference on September 29, 2022, at the Sofitel Hotel, New York. CEO Steven Fruchtman will present a corporate overview, followed by a 10-minute analyst-led fireside chat at 12:00 p.m. ET. The presentation will be available online and archived for 90 days. Onconova is focused on developing novel cancer treatments, including the multi-kinase inhibitor narazaciclib and rigosertib for KRAS+ non-small cell lung cancer.
FAQ
What is the market cap of Traws Pharma (ONTX)?
What does Onconova Therapeutics, Inc. specialize in?
What are the key product candidates of Onconova Therapeutics?
What recent achievements has Onconova made?
When is the next conference call scheduled?
How does Onconova's proprietary chemistry platform benefit cancer treatment?
What is Onconova's approach to improving cancer treatment outcomes?
How does Onconova keep stakeholders informed about its progress?
What is the significance of rigosertib in Onconova's research?
How can interested parties participate in Onconova's conference calls?
What is the trading symbol for Onconova Therapeutics, Inc.?
